

## SGN-35T

An investigational CD30-directed, next-generation antibody-drug conjugate with novel tripeptide linker

### Anti-CD30 monoclonal antibody


Chimeric IgG1 antibody that binds to human CD30

### MMAE

Microtubule-disrupting agent

### Protease-cleavable tripeptide linker

Designed to improve preferential cleavage in target cells



### Target: CD30

- CD30 is expressed in many B- and T-cell lymphomas, while having limited expression in normal tissue<sup>1</sup>

### Proposed Mechanism of Action<sup>2-3,a</sup>

- Direct cytotoxicity
- CD30+ Treg depletion
- Bystander effect
- Immunogenic cell death


**CD30:** cluster of differentiation 30; **IgG1:** immunoglobulin G1; **MMAE:** monomethyl auristatin E

<sup>a</sup>Based on preclinical data

1. Wahl AF. Cancer Res. 2002; 3736-42. 2. Hamblett K. EORTC 2023: Poster C132. 3. O'Connor BP. SITC 2023: Poster 1155.


**The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.**





### Proposed Mechanism of Action<sup>1,2,a</sup>

- 1 Binds to CD30
- 2 Complex internalization and MMAE release
- 3 Cell cycle arrest and apoptotic cell death



**CD30:** cluster of differentiation 30; **MMAE:** monomethyl auristatin E; **Treg:** regulatory T cell

<sup>a</sup>Based on preclinical data

1. Hamblett K. EORTC 2023: Poster C132. 2. O'Connor BP. SITC 2023: Poster 1155.

### Clinical Trials



**NOT YET RECRUITING**

**SGN35T-001: Lymphomas (NCT06120504)**  
SGN-35T

Phase 1    Phase 2    Phase 3

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

**The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.**